53 completed, 35 unknown, 20 recruiting, 9 not yet recruiting. 134 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 134 | Completed 53, Unknown 35, Recruiting 20, Not yet recruiting 9, Terminated 9, Withdrawn 3, Active not recruiting 2, Enrolling by invitation 2, Suspended 1 |
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study) Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight, Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight - Aortic Stenosis, Severe Aortic Stenosis | Phase 4 | Not yet recruiting | University of Alberta | 600 | 2026-12-01 | 2026-10-27 |
| Superficial Parasternal Block Combined With Rectus Sheath Block for Open Cardiac Surgery Parasternal and rectus sheath block, ropivacaine 0.25 % - Cardiac Valve Disease, Coronary Heart Disease | Phase 4 | Not yet recruiting | Hôpital du Valais | 100 | 2026-11-01 | 2026-10-22 |
| Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Nanchang University | 115 | 2026-09-01 | 2026-09-08 |
| Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR) Angiotensin Receptor Blocker (ARB) - Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy | Phase 4 | Not yet recruiting | Seoul National University Hospital | 632 | 2026-08-15 | 2026-07-29 |
| STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy - Heart Failure With Reduced Ejection Fraction, Heart Failure | Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-08-12 | 2026-09-02 |
| Selection of Transcatheter Heart vaLve With Intermediate Sizing in Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacement Transcatheter Heart Valve - Aortic Stenosis, Severe | Phase 4 | Not yet recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 604 | 2026-08-01 | 2026-07-08 |
| Efficacy of Verciguat in TR and RV Failure Vericiguat - HFrEF, Tricuspid Regurgitation (TR) | Phase 4 | Not yet recruiting | Daejeon St. Mary's hospital | 100 | 2026-07-01 | 2026-06-25 |
| Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition - Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy | Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-05-20 | 2026-09-02 |
| Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy Aficamten - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Recruiting | Oregon Health and Science University | 40 | 2026-05-05 | 2026-05-20 |
| Echo-Guided vs Fluoroscopy-Guided Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis（ECHO-TAVR） Echocardiographic guidance, Fluoroscopic guidance - Aortic Stenosis, TAVI | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 212 | 2026-04-26 | 2026-04-21 |
| Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery fresh frozen plasma, prothrombin complex concentrate - Cardiac Valve Disease | Phase 4 | Recruiting | Konkuk University Medical Center | 100 | 2026-03-27 | 2026-06-17 |
| Patient Quality of Recovery After TAVR With Different Sedation Regimens Propofol, Dexmedetomidine, Midazolam - Transcatheter Aortic Valve Replacement (TAVR), Aortic Valve Stenosis | Phase 4 | Recruiting | David Lyubashevsky | 126 | 2026-03-16 | 2026-04-29 |
| The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 132 | 2026-03-01 | 2026-09-15 |
| Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery Ferric derisomaltose, Placebo (0.9% saline) - Anemia, Iron Deficiencies | Phase 4 | Not yet recruiting | Yonsei University | 180 | 2025-12-01 | 2025-11-20 |
| Perioperative Intensive Statin Therapy for Neuroprotection in TAVR（PISTNT） Intensive statin treatment, Placebo Control - Aortic Stenosis, Cerebral Ischaemic Injury | Phase 4 | Not yet recruiting | Pan Xiangbin | 500 | 2025-10-01 | 2025-07-28 |
| STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel - Mitral Regurgitation | Phase 4 | Recruiting | Chinese Academy of Medical Sciences, Fuwai Hospital | 1032 | 2025-07-31 | 2026-03-09 |
| Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery. Losartan 50 mg, Placebo - Heart Valve Diseases, Left Ventricle Remodeling | Phase 4 | Recruiting | Vitor Emer Egypto Rosa | 60 | 2025-07-01 | 2025-08-01 |
| STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel - Mitral Regurgitation | Phase 4 | Recruiting | Chinese Academy of Medical Sciences, Fuwai Hospital | 880 | 2025-06-13 | 2026-03-09 |
| Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial SGLT2 inhibitor (Dapagliflozin 10mg) - Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF) | Phase 4 | Recruiting | The University of Hong Kong | 106 | 2025-05-12 | 2026-10-28 |
| TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System VitaFlow+GDMT, J-Valve+GDMT - AORTIC VALVE DISEASES, Aortic Regurgitation | Phase 4 | Recruiting | Ruijin Hospital | 120 | 2025-04-29 | 2026-01-30 |
Showing 20 of 134. Sign in to see all of them.
Aortic Valve Stenosis (53) · Mitral Valve Insufficiency (18) · Cardiomyopathy, Hypertrophic (14) · Coronary Artery Disease (14) · Aortic Valve Disease (12) · Heart Failure (9) · Hemorrhage (8) · Aortic Valve Insufficiency (7) · Stroke (7) · Atrial Fibrillation (6) · Cardiovascular Diseases (6) · Hypertrophy, Left Ventricular (6) · Mitral Valve Stenosis (6) · Myocardial Infarction (6)
Heart Diseases (130) · Cardiovascular Diseases (128) · Aortic Valve Disease (69) · Ventricular Outflow Obstruction (54) · Pathological Conditions, Signs and Symptoms (41) · Vascular Diseases (35) · Pathologic Processes (30) · Myocardial Ischemia (21) · Aortic Valve Stenosis (16) · Aortic Stenosis, Subvalvular (14) · Arterial Occlusive Diseases (14) · Arteriosclerosis (14) · Cardiomyopathies (14) · Coronary Disease (14)
Aspirin (8) · Clopidogrel (6) · Propofol (6) · Metoprolol (5) · Saline Solution (5) · Warfarin (5) · Dexmedetomidine (4) · Sodium Chloride (4) · Adrenergic beta-Antagonists (3) · Bisoprolol (3) · Dabigatran (3) · MYK-461 (3) · Rivaroxaban (3) · Simendan (3) · Ticagrelor (3)
Yonsei University (5) · St. Antonius Hospital (4) · Washington University School of Medicine (4) · Asan Medical Center (3) · China National Center for Cardiovascular Diseases (3) · Insel Gruppe AG, University Hospital Bern (3) · Konkuk University Medical Center (3) · Mayo Clinic (3) · Abbott Medical Devices (2) · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (2) · Chinese Academy of Medical Sciences, Fuwai Hospital (2) · Copenhagen University Hospital, Rigshospitalet (2) · Duk-Woo Park, MD (2) · Duke University (2) · Kyungsub Song (2)
United States (21) · South Korea (20) · China (13) · Spain (9) · Denmark (8) · Canada (7) · Switzerland (6) · Belgium (5) · Netherlands (5) · Brazil (4) · Finland (4) · Germany (4) · Italy (4) · Poland (4) · Hong Kong (3)
Duk-Hyun Kang, M.D. (3) · Brian R. Lindman, MD (2) · Seung-jung Park, MD (2) · Xiangbin Pan, MD,PhD (2) · Alan Moody, MD (1) · Alexander Cherniavskiy, MD, PhD (1) · Andres Iniguez Romo, MD;PHD (1) · Antonio Marzocchi, MD (1) · Azad Mashari, MD (1) · Barbara Brzeska, MD (1) · Benjamin Chow, MD (1) · Brian P Griffin, M.D. (1)
PMID 20961243, PMID 28527771, PMID 30621974, PMID 41616808, PMID 14771796, PMID 16363316, PMID 16438759, PMID 16980116, PMID 17218108, PMID 17572925, PMID 17698822, PMID 18268152, PMID 19336502, PMID 19762550, PMID 20096533, PMID 20139439, PMID 20334810, PMID 20566953, PMID 20837828, PMID 20837893, PMID 20970202, PMID 21098354, PMID 21216739, PMID 21258075, PMID 21403014, PMID 22154789, PMID 22281799, PMID 22447809, PMID 22898522, PMID 23236027, PMID 23583252, PMID 24682842, PMID 26114442, PMID 26139739, PMID 26437535, PMID 26661319, PMID 26914224, PMID 26920599, PMID 27465213, PMID 29222139, PMID 29281101, PMID 29604289, PMID 29663436, PMID 30255476, PMID 30586756, PMID 30908754, PMID 30995208, PMID 31020819, PMID 31200756, PMID 31351553
2023 (3), 2016 (1)